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Glycoxidation and inflammatory markers in patients on treat-
ment with PMMA-based protein-leaking dialyzers.
Background. High-molecular-weight solutes such as glyca-
tion and oxidation protein products are putative proinflamma-
tory mediators found in the uremic blood. The elimination of
these and other large solutes by protein-leaking dialyzers (PLD)
might help to correct the inflammatory status of maintenance
hemodialysis (HD) patients.
Methods. Two matched groups of 13 standard 3 times/week
HD patients were treated for 6 months with PMMA-based
PLD and non–protein-leaking dialyzers (NPLD), respectively.
At baseline, 1, 3, and 6 months, we measured the blood lev-
els of the inflammatory cytokines IL-1b , TNF-a, IL-6, the
acute-phase protein C-reactive protein (CRP), the adhesion
molecules ICAM-1, VCAM-1, and selectine-E, the chemotaxis
factors MCP-1, and the glycation and oxidation protein end
products pentosidine, protein carbonyls, and AOPP.
Results. In all the patients at baseline, pre-HD levels of glyca-
tion and oxidation protein markers, and inflammatory param-
eters were significantly higher than in healthy control subjects
(P < 0.01 or greater). After 6 months, in the group on treat-
ment with PLD, but not in that on NPLD, there was a signifi-
cant decrease (P < 0.05 or greater) of pre-HD values of total
pentosidine (mainly represented by pentosidine in serum albu-
min; −43%), protein carbonyls (−42%), AOPP (−38%), and
the inflammatory cytokines IL-1b (−49%), IL-6 (−39%), and
TNF-a (−20%), while IL-10 and INF-c increased by 67% and
37%, respectively. Proinflammatory cytokines, and particularly
IL-6, showed a positive correlation with the levels of circulat-
ing pentosidine. Protidemia was not significantly modified at
the end of the study in both the groups.
Conclusion. The results in this pilot study show that the re-
moval of large solutes by PLD can improve some indices of
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chronic inflammation in HD patients. Further studies are re-
quired to determine the relevance of the individual solutes re-
moved with PLD as proinflammatory mediators in the uremic
environment.
Several high-molecular-weight solutes (HMW) with
the nature of “proteinaceous” toxins have been identi-
fied in the uremic blood (reviewed in [1–4]), and can con-
tribute as a key pathogenetic factor in the multifactorial
condition of chronic inflammation observed in hemodial-
ysis (HD) patients. Among these, glycation and oxida-
tion protein products were described as mediators of
inflammation and vascular damage [5–9]. In fact, these
toxins are scavenged by inflammatory and endothelial
cells through a specific and inducible receptor-dependent
mechanism that ultimately can sustained phagocyte respi-
ratory burst, cytokine and adhesion molecule production,
and chemotaxis [10–14].
The accumulation of HMW in the uremic blood and
the consequent stimulation of scavenger receptor ex-
pression may produce a self-feeding inflammatory loop
(Fig. 1) centered on the simultaneous role of inflamma-
tory cells as scavengers and generators of proinflamma-
tory HMW. Little information is available on the role
that dialysis procedures may play to neutralize this ad-
verse cycle. However, even the most efficient dialysis
procedures currently in use obviously do not provide ad-
equate correction of the blood levels of HMW toxins,
such as AGEs and protein oxidation end products. A
way of breaking this loop may be that of removing or
reducing the formation rate of proinflammatory solutes
such as HMW or cytokines. Preliminary findings showed
that this could be achieved by adsorption of so far poorly
characterized compounds to resins or dialysis membrane
surfaces. Morena et al [15] recently showed that sor-
bent resins could selectively remove from the uremic
plasma unidentified solutes that are responsible of the in
vitro RAGE-dependent activation of monocyte-like cells.
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Fig. 1. Events that may contribute to sustain
the chronic inflammatory syndrome of HD
patients. This model depicts how the accumu-
lation in the uremic blood of high-molecular-
weight toxins (HMW), such as glycation and
oxidation protein products, and the conse-
quent stimulation of scavenger receptor (SR)
expression, may contribute to a self-feeding
adverse cycle that sustain the multifactorial
inflammatory state observed in HD patients.
A key element in this cycle is the concomi-
tant role of inflammatory leukocyte as scav-
engers and generators of glycation and oxida-
tion protein products. Other contributors to
this loop could be a slackened catabolism of
modified proteins and the poor de novo syn-
thesis of serum proteins by the inhibitory ef-
fect that inflammatory cytokines, such as IL-6,
exert on liver cells. Other metabolic responses
to chronic inflammation in different tissues
might further sustain protein damage by lead-
ing to cytokine secretion, oxidative and car-
bonyl stress. These aspects can feed another
important element in this loop, which is the
impaired IL-10–dependent negative feedback
on monocyte activation by T helper lympho-
cytes. Further details and bibliography are re-
ported in the text.
Other authors demonstrated that polymethylmethacry-
late (PMMA) membranes could adsorb proinflammatory
cytokines, such as TNF-a and IL-6, thus representing an
interesting tool for the treatment of acute and chronic
inflammatory conditions [16].
Another strategy may be that of increasing the re-
moval of inflammatory solutes by a higher dialysis mem-
brane permeability. In the last years, protein-leaking di-
alyzers (PLD) have been introduced in the practice of
extracorporeal dialysis [17, 18]. Previously, we [19] and
other groups [20] provided the evidence that PMMA-
based PLD can remove HMW solutes such as ery-
throid cell proliferation inhibitors [21] and mononu-
clear leukocyte proapoptotic factors [22]. Again, both
the polysulfone-based [23] and PMMA-based PLD [24]
steadily reduce pre-HD plasma levels of the protein-
bound amino acid homocysteine, a proposed indepen-
dent risk factor of atherosclerotic cardiovascular disease
[25].
However, the contribution that PLD may give to con-
strain chronic inflammation and the accumulation of
HMW with proinflammatory activity remains so far un-
investigated. This controlled 6-month pilot study was
designed to preliminarily investigate whether, and to
what extent, PLD compared to standard non–protein-
leaking dialyzers (NPLD) can affect the levels of some
indices of chronic inflammation, namely the proinflam-
matory cytokines IL-1b , TNF-a, IL-6, the acute-phase
marker C-reactive protein (CPR), the immunomodula-
tory cytokines INFc and IL-10, and some HMW solutes
with putative proinflammatory activity, such as the AGE
marker pentosidine and the oxidation protein end prod-
ucts AOPP and protein carbonyls.
METHODS
Patients, dialysis characteristics, and study protocol
Patients, study design, and dialysis characteristics were
published in detail in [24]. Briefly, the participants in-
cluded in the study (N = 26, M = 14 and F = 12, mean
age = 66.1 ± 17.1 years) were patients on standard 3
times/week bicarbonate HD (mean dialysis age = 47.1 ±
40.8 months). Specific exclusion criteria were acute and
chronic infectious disease, malnutrition (serum albumin
cut-off <3.3 g/dL), and malignancy.
The study was designed as a 6-month prospective con-
trolled trial. A preliminary 3-month washout step was
carried out in order to stabilize the patients on treat-
ment with baseline NPLD including high-flux PMMA
(B1 series; Toray, Tokyo, Japan), low-flux cellulose ac-
etate (Kobe, Japan), and cuprammonium rayon (Terumo,
Japan). Then, the patients were randomly assigned to two
groups (N = 13 each). The first group (control group)
was maintained on treatment with the same type of di-
alyzers used at the inclusion, while in the second group
(study group), the patients were switched to the treat-
ment with PMMA-based PLD (BK-F series, Toray). That
was the only change introduced in the dialytic treatment.
Accordingly, Kt/V values checked every 3 months were
not significantly different in the study group and control
group at baseline and throughout the entire study. Other
patient characteristics in the control and study group are
reported in Table 1.
The dose of erythropoietin (EPO) administered was
maintained unchanged throughout the study. Only mi-
nor adjustments to other pharmacologic therapies were
made when required. In particular, blood pressure
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Table 1. Main characteristics at the inclusion in the study of patients
on treatment with NPLD (control group) and PLD (study group)
Control group Study group
(N = 13) (N = 13)
Sex M = 7; F = 6 M = 7; F = 6
Age years 62.6 ± 12.0 67.6 ± 14.8
Dialytic age months 49.3 ± 31.8 46.8 ± 38.2
Membrane type B1 = 4; CA = 5; B1 = 5; CA = 4;
CR = 4 CR = 4
Kt/V weekly 3.9 ± 0.7 4.1 ± 0.7
Urea mg/dL 149.6 ± 43.4 153.4 ± 49.8
Creatinine mg/dL 9.8 ± 1.9 9.7 ± 2.3
Residual CrCl mL/min <1 <1
Hematocrit% 33.0 ± 3.6 32.5 ± 4.1
Cholesterol mg/dL 195.4 ± 35.2 189.8 ± 55.7
Tryglycerides mg/dL 175.5 ± 123.2 179.1 ± 137.0
Total proteins g/dL 6.7 ± 0.4 6.9 ± 0.5
Albumin g/dL 4.1 ± 0.3 4.0 ± 0.4
Folic acid ng/mL 22.9 ± 18.0 23.3 ± 19.5
Vitamin B12 pg/mL 375.9 ± 160.5 379.3 ± 169.5
tHcy lmol/L 26.6 ± 5.0 25.3 ± 5.9
Abbreviations found in the text.
management was adjusted in order to achieve steady sys-
tolic and diastolic blood pressure values in all the subjects
during the study. The number of patients on treatment
with ACE inhibitors and the dose administered were not
statistically different in the 2 groups.
BK-F membranes (1.6 m2 of surface area) have a pore
size of 100 A˚ and 62% porosity, resulting in a nominal
cut-off >70 kD, a value of UFR in vitro of 2000 mL/hr at
100 mm Hg, and a sieving coefficient for albumin of c.a.
0.03 (data provided by the manufacturer).
Blood and dialysate flows were 250 mL/min and
500 mL/min, respectively. The dialysate quality was the
highest available as routinely evaluated by LAL test, and
was maintained the same during the entire study.
A group of 15 sex- and age-matched healthy control
subjects was also studied (M = 8 and F = 6, mean age =
51.6 ± 13.9 years).
Informed consent was obtained from each subject at
the enrollment. The study was approved by the local eth-
ical committee.
Sample collection and analyses
Blood sampling was carried out in the midweek dialysis
at baseline and after 1, 3, and 6 months of treatment with
NPLD and PLD. Sufficient amounts of blood were drawn
by vacutainer technique into heparinized green-top tubes
before (pre-HD) and after HD (post-HD). The tubes
were centrifuged and plasma was collected and stored
at −20◦C until assessed in plastic Eppendorf tubes. An
aliquot of each blood sample was immediately used for
the routine analysis of hematochemical parameters.
Serial sampling of spent dialysate (5 L every 10 min)
was performed during the entire dialysis session to mea-
sure the time-course and extent of protein leakage. More-
over, from the 10th to 50th minute of HD the total spent
dialysate was collected into sterile tanks at baseline and
at the first dialysis with PLD. The samples were then con-
centrated by an ultrafiltration cassette (membrane cut-off
10 kD; Pall Gelman Laboratory, Milan, Italy), and 5 mL
aliquots were stored at −80◦C until processing to evaluate
AGE-proteins and the protein pattern by electrophoresis
(see below).
Protein glycation and oxidation markers
Pentosidine. At all the experimental time points in
the study, pentosidine as marker of protein glycoxida-
tion was measured in plasma and spent dialysate by
high-performance liquid chromatography (HPLC) anal-
ysis according to the procedures described previously
[26, 27]. The free form (f-pentosidine) and the total pro-
tein and albumin-bound fractions of pentosidine (total
pentosidine and albumin-pentosidine, respectively) were
assessed by measuring in duplicate pentosidine concen-
trations before and after deproteinization of plasma
samples with 10% trichloroacetic acid (TCA) or ultra-
filtration with mini-prep 10 kD cut-off concentrators
(Alltech, Milan, Italy). Further purification by ion ex-
change or affinity chromatography was required to mea-
sure albumin-pentosidine levels. Pentosidine in spent
dialysate samples was measured with the same method
used for the analysis of plasma after protein concentra-
tion carried out by the ultrafiltration procedure described
above.
Protein carbonyls and advanced oxidation protein
products (AOPP). Protein carbonyls and AOPP were
measured at baseline and after 6 months in the study. Pro-
tein carbonyls in plasma and spent dialysate samples were
measured using the reagent 2,4-dinitro-phenyhydrazine
(DNP), as described in [28]. AOPP were measured by
spectrophotometric analysis at 340 nm as described in [5].
This assay was reported to mainly recognize di-tyrosine
as protein oxidation product in serum proteins.
Analysis of the protein pattern in the spent dialysate
The protein pattern in dialysate samples was as-
sessed by 4% to 15% gradient sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE); the
densitometric analysis of the protein bands was per-
formed using the software Quantity One (Bio-Rad,
Hercules, CA, USA). The total protein concentration in
the samples of spent dialysate used for the SDS-PAGE
analysis was determined as described before [24].
Cytokines, CRP, adhesion molecules, and MCP-1
Blood levels of IL-1b , TNF-a, IL-6, and CRP were as-
sessed at all the experimental time points in the study,
while INF-c, IL-10, the adhesion molecules ICAM-1,
VCAM-1, selectin-E, and the chemotaxis factor MCP-
1 were assessed at baseline and at the end of the study
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Table 2. Pre-HD levels of proteins, protein glycation and oxidation indices, cytokines and CRP, adhesion molecules, and MCP-1 in the plasma of
patients at baseline and after 6 months (end of the study) of treatment with PLD (study group) and NPLD (control group)
Control group on NPLD Study group on PLD
Healthy
subjects Baseline 6 months Baseline 6 months
Plasma proteins and glycoxidation markers
Plasma proteins g/dL 7.6 ± 1.3 6.7 ± 0.4 6.7 ± 0.9 6.9 ± 0.5 6.8 ± 0.6
Albumin g/dL 4.5 ± 0.9 4.1 ± 0.3 3.9 ± 0.8 4.0 ± 0.4 3.8 ± 0.4
Transferrin mg/dL 272.4 ± 98.2 260.0 ± 81.9 252.9 ± 67.7 256.4 ± 57.1 264.3 ± 68.5
f-pentosidine pmol/mL plasma N.D. 110.4 ± 30.2 112.5 ± 27.6 106.1 ± 24.0 60.2 ± 18.9b
Total pentosidine pmol/mg protein 1.4 ± 0.3d 26.5 ± 8.7 25.0 ± 11.1 23.5 ± 9.3 15.4 ± 5.2b
Albumin-pentosidine pmol/mg albumin 5.4 ± 4.6d 38.1 ± 16.6 37.9 ± 18.0 36.3 ± 14.2 23.8 ± 8.9b
Protein carbonyls arbitrary units 39.1 ± 30.2d 260.5 ± 165.6 245.2 ± 177.0 229.8 ± 156.8 132.2 ± 117.5b
AOPP arbitrary units 12.7 ± 14.0d 100.3 ± 68.6 114.1 ± 78.3 104.7 ± 60.2 64.6 ± 56.6b
Cytokines and CRP
IL-1b pg/mL 2.7 ± 1.1d 4.4 ± 3.0 4.8 ± 2.2 4.1 ± 3.3 2.1 ± 1.9a,e
TNF-a pg/mL 9.1 ± 3.2d 19.0 ± 4.0 21.0 ± 5.5 18.7 ± 4.3 15.1 ± 3.1b
IL-6 pg/mL 2.4 ± 0.9d 5.3 ± 2.1 5.8 ± 2.3 5.0 ± 1.9 3.1 ± 0.6b,f
IL-10 pg/mL 6.0 ± 2.5d 3.3 ± 0.4 3.0 ± 0.5 3.0 ± 0.6 5.0 ± 4.4b,e
INF-c pg/mL 12.7 ± 3.2c 9.9 ± 1.5 10.9 ± 1.9 9.2 ± 1.6 12.6 ± 1.7b
CRP mg/L 7.9 ± 3.6d 25.8 ± 28.6 27.4 ± 24.0 22.7 ± 33.9 12.1 ± 9.1
Adhesion molecules and MCP-1
ICAM-1 ng/mL 232.5 ± 89.6 283.4 ± 65.3 282.9 ± 96.5 270.7 ± 77.8 240.8 ± 67.6
VCAM-1 ng/mL 589.0 ± 171.4d 973.6 ± 435.9 938.5 ± 259.9 941.0 ± 458.2 772.3 ± 285.4
Selectin-E ng/mL 48.4 ± 16.5 63.5 ± 30.5 68.2 ± 26.9e 58.2 ± 27.3 63.2 ± 36.7
MCP-1 pg/mL 207.3 ± 91.5d 420.1 ± 154.9 468.9 ± 182.5 408.8 ± 170.2 381.5 ± 141.5
N.D., not detectable. Data are mean ± 1 SD.
aP < 0.05 and bP < 0.01 vs. baseline values.
cP < 0.05 and dP < 0.01 vs. patients’ data (when not otherwise specified).
eP < 0.05 and fnot significant vs. healthy control subject data.
(6 months). All these indices were assessed at the
same day and in the same laboratory using high-
sensitivity immunoenzymatic kits (Cytimmune Science,
Inc., Rockville, MD, USA or R&D Systems, Inc., Min-
neapolis, MN, USA). All the analyses were performed
following the recommendations of the manufacturers.
According with preliminary evaluations and manufac-
turer information, the average intra- and interassay vari-
ability for the different test kits was observed to be ≤5%
and <10%, respectively.
Data analysis and statistics
Data were expressed as mean ± 1 standard deviation
(SD) or median (range).
Statistics were carried out using the software Stat-
View 5.0 for Windows (SAS Institute, Inc., Cary, NC,
USA). The Student–Newman-Keuls (SNK) test for mul-
tiple comparisons was applied to evaluate differences be-
tween the groups of patients. The nonparametric one-way
analysis of variance (ANOVA) and Wilcoxon’s tests were
used to compare data within the same group of patients
at the different time points in the prospective study (re-
peated measures).
The correlation between inflammatory and protein gly-
coxidation markers was investigated by either bivariate
or multivariate regression analysis using the specific op-
tions of the software MicrocalTM Origin 6 (Microcal Soft-
ware, Inc., Northampton, MA, USA). This software uses
the ANOVA test for multivariate analyses.
Probability values (P) of < 0.05 were accepted, and
values ≤ 0.01 were considered highly significant.
RESULTS
Effect of PLD on hematochemical parameters
As previously described [24], all the main hemato-
chemical parameters did not change significantly in the
PLD and NPLD group during the study, with the excep-
tion of hematocrit, which at baseline was 32.5 ± 4.1%,
and then increased progressively to reach a mean value
of 37.1 ± 3.8% at the end of the study (P < 0.01).
Compared to baseline evaluation total proteins, albu-
min, prealbumin, and transferrin levels did not change, or
just slightly decreased at the end of the study in the group
on PLD (Table 2). However, the data in Figure 2 show
that after the first month of treatment PLD membranes
lead to a significant even though transient decrease of
both total proteins and albumin levels (−9% and −8%,
respectively, vs. baseline evaluation; P < 0.05). Transfer-
rin levels also decreased by 12% (P < 0.05), and then re-
turned within the normal control range at 3 and 6 months.
Only one patient (Fig. 2) had a decrease of plasma albu-
min at 1 month that exceeded the values used as exclusion
criteria, but after further observations a prompt recovery
was observed, and then both total proteins and albumin
returned above the cut-off values. Another patient un-
derwent a progressive decline of serum albumin levels,
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Fig. 2. Levels of total proteins (left panel)
and albumin (right panel) in the plasma of pa-
tients on treatment with PMMA-based PLD.
The individual data and the box chart for each
parameter measured at baseline and after 1,
3, and 6 months of treatment with PLD are
shown. In the box chart square symbol, hori-
zontal line into the box, upper and lower lim-
its of the box, and the two asterisks represent
median, mean, 25% to 75% confidence limits,
and range, respectively. The horizontal dotted
lines in the two panels show the mean healthy
control values of the serum protein concentra-
tion and albuminemia, and the straight line in
the right panel represents the cut-off limit for
the albuminemia set as exclusion criteria in
this study (see text).
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Fig. 3. Levels of free (f-pentosidine, left panel), total (total pentosidine, middle panel), and albumin-bound pentosidine (albumin-pentosidine,
right panel) in the group of patients on treatment with PMMA-based PLD. Data are shown as described in the legend to Figure 2. The horizontal
dotted lines represent the mean value + 1 SD of the levels of the three parameters as measured in the group of healthy control subjects.
but this exceeded the cut-off limit only at the end of the
study (Fig. 2).
PTH levels and calcium phosphorus product were not
affected by the dialysis membranes investigated in the
study.
Free and protein-bound pentosidine
Table 2 shows mean baseline and 6-month con-
centrations of pentosidine (as f-pentosidine, albumin-
pentosidine, and total pentosidine fractions) in the
plasma of the 2 groups of patients on treatment with
PLD and NPLD dialyzers before dialysis (pre-HD) and
in healthy control subjects. At baseline, HD patients
showed a very significant (P < 0.001) accumulation of
f-pentosidine, albumin-pentosidine, and total pentosi-
dine that were, respectively, not detectable, and more
than 6-fold and 15-fold lower in the healthy control sub-
jects. The albumin-pentosidine adduct represents more
than 95% of the total pentosidine. The treatment with
PLD and NPLD produced the same intra-HD drop
of f-pentosidine with median values of 27% (11–39%)
and 25% (6–32%), respectively, while protein-bound
pentosidine decreased by 12% (6–20%) during a sin-
gle HD session only in the subjects on treatment with
PLD.
Figure 3 shows individual values and data distribution
of pre-HD plasma levels of the different forms of pen-
tosidine measured in the PLD group during the differ-
ent time points in the study. In these patients, the lev-
els of f-pentosidine markedly decreased during the first
month of dialysis (−27% vs. baseline values, P < 0.01),
and further decreased after 3 and 6 months of treat-
ment (−39% and −43%, respectively). The time course
of albumin-pentosidine levels showed a significant de-
crease at 1 month of treatment (−37%, P < 0.001); then
the levels remained almost unchanged during the other
experimental times (−41% and −34% at 3 and 6 months
of treatment, respectively). Both the f-pentosidine and
albumin-pentosidine did not change in the control group
on treatment with NPLD during the entire span of the
study (Table 2). As a general finding, we observed that
the levels of both the f-pentosidine and total pentosidine
showed a marked interindividual variability particularly
at baseline evaluation, and the magnitude of the changes
of these parameters found during the first month of treat-
ment with PLD was proportional to the values observed
at baseline (R2 = 0.173, P < 0.05).
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Protein oxidation indices
Pre-HD levels of AOPP and protein carbonyls mea-
sured at baseline and after 6 months are shown in Table 2.
Similar to pentosidine, these protein damage indices
were, respectively, more than 6- and 8-fold higher in HD
patients than in healthy subjects (P < 0.01 or higher).
Compared to baseline values, after 6 months of PLD, pro-
tein carbonyls and AOPP decreased by 43% and 38%,
respectively, but did not change in the NPLD group. In
the study and control group, the intra-HD decrease of
protein carbonyls was (median values) 16% and 18%,
respectively, and AOPP decreased by 2% and 1%, re-
spectively.
The bivariate regression analysis between protein car-
bonyls and AOPP assessed cumulatively at baseline and
6 months in the 2 groups of patients showed a positive
correlation (R2 = 0.220; P = 0.006). The levels of total
pentosidine were not significantly correlated with protein
carbonyls or AOPP levels.
Cytokines and CRP
Table 2 shows pre-HD levels of cytokines and CRP at
baseline and after 6 months of treatment with PLD and
NPLD.
In the 2 subgroups of patients, baseline pre-HD levels
of cytokines and CRP were similar. In the patients, the
levels of IL-1b( TNF-a( IL-6, and CRP were increased
(P < 0.05 or greater), while IL-10 and INF-c levels were
lower than in healthy control subjects (P < 0.01 and P <
0.05, respectively). In the group on NPLD, pre-HD lev-
els of all the inflammatory indices remained almost un-
changed throughout the study. On the contrary, major
differences were found in pre-HD levels of cytokines and
CRP in the study group. As shown in detail in Figure 4, af-
ter the first month of treatment with PLD, plasma concen-
trations of IL-6 and IL-1b decreased by more than 20%
compared to baseline evaluations, and after 6 months
their levels further decreased by 39% (P < 0.01) and
49% (P < 0.05), respectively. TNF-a levels showed a less
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pronounced decrease that was significant only after 1
(12%, P < 0.05) and 6 months (20%, P < 0.01) of treat-
ment with PLD.
Also, mean CRP levels progressively decreased dur-
ing the treatment with PLD compared to baseline eval-
uation. However, the striking interindividual variability
observed for this parameter did not permit the statistical
significance observed for the other inflammatory param-
eters assessed at the different time points in the study to
be reached.
Compared to baseline evaluations, the levels of IL-10
and INF-c (Table 2) significantly increased after 6 months
of treatment with PLD (P < 0.05).
Both the data distribution and the changes observed
in the inflammatory markers at the different time points
in the study in the 2 subgroups of patients were clearly
independent from the type of membrane used at baseline.
As far as it concerns the intra-HD changes of cytokines
and CRP, this was negligible in the study group on PLD
at baseline (<7%), and almost absent (<2%) during the
other time points in the study (not shown). The same
finding was obtained in the group of patients on NPLD.
A positive correlation (bivariate analysis) was ob-
served at the different time points in the study between
the levels of IL-6 and pentosidine as both the albumin-
pentosidine and total pentosidine forms (R2 = 0.523,
P ≤ 0.0001 and R2 = 0.486, P < 0.0001, respectively).
The correlation between IL-6 and f-pentosidine was also
highly significant, although less pronounced (R2 = 0.249,
P ≤ 0.005). Similarly, IL-1b positively correlated with
albumin-pentosidine (R2 = 0.532, P < 0.0001) and total
pentosidine (R2 = 0.519, P < 0.0001), but TNFa levels
correlated only with albumin-pentosidine (R2 = 0.287,
P < 0.05).
In a model of multivariate regression analysis, the high-
est correlation score was observed when the pre-HD lev-
els of IL-6 were set as the independent variable and were
matched with the pairs of dependent variables IL-1b and
TNF-a (adjusted R2 = 0.634, P < 0.0001) or albumin-
pentosidine and f-pentosidine (adjusted R2 = 0.489, P <
0.0001).
AOPP and protein carbonyls were not significantly cor-
related with the levels of inflammatory cytokines either
in the bivariate and multivariate tests (not shown).
Adhesion molecules and MCP-1
In both the study and control group, baseline pre-HD
levels of the adhesion molecules ICAM-1 and selectine-
E were slightly higher, and VCAM-1 was significantly
higher (P < 0.05) than in healthy subjects (Table 2). These
parameters did not show any significant change during the
study in both the groups of patients investigated. Base-
line pre-HD levels of MCP-1 were significantly higher
in the subgroups of patients than in healthy control sub-
jects (P < 0.01) and slightly decreased after 6 months of
treatment with PLD (Table 2). Adhesion molecules and
MCP-1 did not correlate with protein damage markers
and inflammatory cytokines.
In both NPLD and PLD group the levels of adhesion
molecules and MCP-1 slightly increased during dialysis
(ranging from 8% to 15% in the different experimental
time points).
Protein pattern and pentosidine in spent
dialysate samples
The kinetic of protein leakage with PLD and the pro-
tein pattern of spent dialysate samples of patients on
PLD and NPLD are shown in Figure 5 (upper panel
and lower panel, respectively). In Table 3 the total and
fractional amount of proteins removed during a single
dialysis session with NPLD and PLD are reported. The
time course of protein leakage by PLD is character-
ized by a peak within the first 30 minutes of dialysis,
followed by a progressive decrease that was particu-
larly marked after the first hour of dialysis. The total
amount of proteins removed with NPLD ranged be-
tween 0.20 and 0.32 g/dialysis session (median = 0.26),
while in the first session of dialysis with PLD this value
ranged between 1.28 and 4.13 g (median = 2.86). The
SPD-PAGE analysis of the protein pattern in dialysate
samples showed that in PLD-treated patients, the ma-
jor serum protein removed was albumin (75.6%), fol-
lowed by transferrin (10.9%), prealbumin (7.1%), IgG
(2.8%), and a1-antitrypsin (1.0%). This pattern widely
matches that of plasma proteins in regards to the relative
abundance of single protein components (not shown).
On the contrary, in NPLD patients, prealbumin was the
major serum protein removed (31.0% of total proteins),
followed by albumin (20.7%), transferrin (17.4%), a1-
antitrypsin (15.5%), and 2 minor unidentified proteins
(9.9% and 5.4%, respectively).
DISCUSSION
Proinflammatory solutes accumulate in the uremic
blood and may contribute to the onset and progression of
the inflammatory syndrome commonly observed in HD
patients [3, 4, 6, 7, 9]. Between these solutes, oxidation
and glycation protein products are known to exert their
proinflammatory function by specific receptor-dependent
activation of inflammatory and endothelial cells [10–14].
Importantly, the circulating levels of these, as well as
other large size solutes, cannot be decreased by conven-
tional dialysis procedures because they are not removed
through the pores of the dialyzer membrane [1, 20] and,
at the same time, dialysis therapies cannot arrest the ad-
verse pathways sustaining their formation rate and/or de-
fective catabolism (such as oxidative stress and glycation,
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Fig. 5. Kinetics of the intra-HD protein leakage observed during
the treatment with the PMMA-based PLD (upper panel) and elec-
trophoretic pattern of the proteins recovered in the spent dialysate of
patients treated with NPLD and PLD (lower panel). Protein leakage by
PLD was calculated by assessing the protein concentrations in aliquots
of spent dialysate collected at different time points during the dialysis
treatment, as described in the section Methods. The SDS-PAGE anal-
ysis of the protein patterns in spent dialysate samples of NPLD and
PLD patients was performed after collection of the total dialysate and
concentration of the proteins by ultrafiltration with a 10 kD cut-off
membrane. MW standards were myosin 200 kD, albumin 66 kD, oval-
bumin 45 kD, carbonic anhydrase 31 kD. Lanes 1 and 2, protein pattern
of the spent dialysate collected from two subjects treated with PS and
cellulose acetate dialyzers, respectively. Lanes 3 and 4, protein pattern
of the spent dialysate collected from two different subjects treated with
PLD. Each lane was loaded with 40 lg of total proteins.
reactive carbonyl accumulation, defective repair, or re-
moval of damaged proteins) [9, 29].
Recent studies have suggested that either adsorption
or filtration techniques may help to reduce the proin-
flammatory charge of the uremic plasma. Sorbent resins,
for instance, were found to capture solutes responsible of
the in vitro RAGE-mediated proinflammatory activity
Table 3. Protein concentration and pattern in the samples of spent
dialysate obtained from patients treated with NPLD and PLD
NPLD PLD
Total proteins g/dialysis session 0.26 (0.20–0.32) 2.86 (1.28–4.13)
Proteins subfractions MW Densitometry
(% of total O.D.)
a1-antitripsin (50) 15.5 1.0
Prealbumin (54–61) 31.0 7.8
Albumin (66) 20.7 75.6
Transferrin (76) 17.4 10.9
IgG (150) N.D. 2.8
Abbreviations are: MW, molecular weight; O.D., optical density; N.D.,
not detectable. The proteins in the dialysis fluids were concentrated and
assessed by SDS-PAGE, as described in detail in Methods. Total protein data
were expressed as median (range). The data of the densitometric analyses
were as percentage of the mean values of total optical density recorded in
each slab gel by laser scan densitometry. The apparent MW (in kD) of the
identified proteins was estimated according with the curves of electrophoretic
mobility of a mixture of reference proteins of known MW (Fig. 5).
of the uremic plasma [15, 30]. Other investigators have
shown that PLD, introduced in the dialysis practice in
the last years, may remove different classes of HMW so-
lutes, also including some unknown proinflammatory tox-
ins [17–21]. Interestingly, PMMA-based PLD have been
reported also to adsorb proinflammatory cytokines [16]
as a specific characteristic that might make these dialyzers
a useful tool in the treatment of both acute and chronic
inflammatory states. However, so far, the effect of these
and other types of PLD on the inflammatory syndrome
of HD patients remains to be investigated.
The current pilot study provides the preliminary evi-
dence of an effective reduction of pre-HD levels of both
indices of protein damage and inflammation in HD pa-
tients treated with PMMA-based PLD. More in detail,
after 6 months of treatment with PLD, the decrease of the
protein damage indices albumin-pentosidine, AOPP, and
carbonyls scored between 32% and 43% of the baseline
values. Both the early and late inflammatory indices IL-
1b and IL-6 achieved a very significant reduction (49%
and 39%, respectively), and TNF-a levels decreased by
20%. In this context, we observed a striking correlation
between the levels of these inflammatory cytokines, and
between inflammation indices (particularly IL-6) and the
protein glycoxidation marker pentosidine. In the group
of patients on PLD the profile of reduction of the levels
of pentosidine and inflammatory cytokines was charac-
terized by a sharp decrease after the first month of the
study, followed by a plateau at 3 and 6 months of treat-
ment. Moreover, the changes on these parameters were
independent from the type of membrane used during the
washout period, and were more pronounced in those pa-
tients showing highest baseline values.
The oxidation markers protein carbonyls and AOPP
measured at baseline and at the end of the study did not
correlate significantly with the levels of inflammatory cy-
tokines and pentosidine. These findings seem to suggest a
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predominant role of protein glycoxidation in the activa-
tion of proinflammatory pathways and cytokine secretion
of these patients.
Between the inflammatory markers, IL-6 and IL-1b
showed the highest responsiveness to PLD treatment,
with the lowest intra- and interindividual variability. On
the contrary, CRP levels did not follow linearly the ki-
netics of the other inflammatory indices, showing major
intra- and interindividual variabilities. Other studies pre-
viously described that CRP levels increase only in some
patients (approximately 50% of the population on main-
tenance extracorporeal dialysis) also depending on differ-
ent clinical and dialysis-related events [31], thus resulting
in poor reliability as marker of chronic inflammation in
small-population short-term studies.
Furthermore, the treatment for 6 months with PLD
in part restored IL-10 and IFNc levels that at base-
line were decreased in the 2 groups of patients, pos-
sibly by the overwhelming stimulation of Th1 leuko-
cytes and unbalanced Th1/Th2 ratio that the uremic
condition and dialysis-related factors may generate in
HD patients [32]. This suggests that the removal of
HMW solutes by the treatment with PLD might help
to reset the overall immunomodulatory role that cells
as the CD4+ lymphocytes and the same activated
monocytes may exert through a balanced secretion
of anti-inflammatory and immunostimulatory cytokines
[33].
Importantly, despite the significant, even though par-
tial, correction of different inflammation-related param-
eters, adhesion molecules and MCP-1 were not sig-
nificantly affected by the treatment with PLD. This
could be the consequence of either the incomplete
correction of inflammation or the need for a longer
time of treatment to achieve significant changes also in
these markers of inflammation-related vascular damage
[33].
The albumin is both quantitatively and qualitatively the
main substrate for the formation of glycation and oxida-
tion protein products in the blood [6, 8] and, once mod-
ified, it is well known to behave as a proinflammatory
HMW toxin by RAGE-dependent scavenging on inflam-
matory and vascular cells [14]. In all the patients at base-
line and in the group on NPLD throughout the entire
study, the amount of pre-HD albumin-pentosidine was
approximately 5-fold higher than in the healthy control
plasma.
Because albumin is quantitatively the most abundant
protein in the spent dialysate of PLD-treated patients,
and pre-HD levels of albumin-pentosidine decreased by
more than 35% already after 1 month on PLD, showing
also a marked correlation with inflammatory cytokines,
we preliminarily examined whether these PLD exert a
direct mass action on this marker of albumin damage.
Though a significant amount of pentosidine is removed
during a single treatment with PLD, that does not ap-
pear to be sufficient to explain the steady pre-HD de-
crease of total pentosidine found already after 1 month
of treatment with PLD. At the same time, the possibil-
ity that PLD may lower the proinflammatory charge of
the uremic blood through an increased intra-HD clear-
ance/adsorption of cytokines appears unlikely because
the intra-HD drop of cytokines levels were similar in the
study group on PLD and in the control group on NPLD.
Therefore, the removal of other small and large MW
solutes together with an overall and progressive improve-
ment of the inflammatory status might lead to an in-
direct effect of PLD on pentosidine levels. That effect
could be caused by a restoration of the metabolism of
this glycoxidation marker by decreasing its formation rate
(Fig. 1) and improving the catabolism of plasma proteins
impaired by the same glycoxidation damage [29]. Accord-
ingly, early work done by our group showed that increas-
ing the HD frequency from a standard 3 times/week to
a daily schedule can significantly, even though partially,
lower plasma protein glycoxidation indices such as to-
tal pentosidine and AGE peptides [26], and an almost
complete correction of AGE markers is achieved in re-
nal transplanted patients [abstract; Galli F et al, J Am Soc
Nephrol 12:A1831, 2001]. Obviously, both daily HD and
transplantation can lead to a better metabolic processing
rather a sustained clearance of these HMW solutes. An
analogous mechanism was suggested to explain the cor-
rection by PLD of other protein-bound toxins, such as
homocysteine [23, 24].
Importantly, a widespread concern about PLD is that
a prolonged use of these membranes might increase the
risk of malnutrition in HD patients, affecting the already
accelerated protein catabolism, amino acid and peptide
leakage, and the defective liver synthesis of albumin [34,
35]. This study carried out on nonseverely malnourished
patients (albumin levels at the inclusion >3.3 g/dL) pre-
liminarily shows that the protein leakage induced by PLD
(average 2.86 and maximum 4.13 g/HD session) can be
easily compensated with the maintenance of blood pro-
tein concentration and other biochemical indices of the
nutritional status (such as serum albumin, prealbumin,
and transferrin) within or close to the normal range. This
compensation might be also the consequence of the par-
tial correction of the inflammation-related imbalance of
the hepatic synthesis of serum proteins, and at the same
time, it suggests that PLD do not provoke the leakage
of nutrients relevant for the protein metabolism (amino
acids, vitamins, and other cofactors). However, it can-
not be ruled out that the selection criteria adopted in
this study and, first and foremost, the absence of se-
vere malnutrition might be required to achieve a suc-
cessful correction of inflammatory markers by the use
of these types of PLD, avoiding also any risk of protein
malnutrition.
Galli and Benedetti et al: Protein-leaking dialyzers and inflammation 759
CONCLUSION
This short-term study preliminarily demonstrates that a
limited protein leakage in nonmalnourished HD patients
might be a helpful strategy to lower some biochemical
indices of chronic inflammation. The achievement of a
steady decrease of the levels of proinflammatory protein
damage products such as AGEs and oxidation protein
products could represent one possible mechanism to at-
tain this effect. Other and so far unknown large solutes re-
moved by PLD could contribute to the proinflammatory
effect of the uremic blood, and may sustain the damage
of serum proteins.
Further studies are required to confirm these prelim-
inary findings and to better evaluate the clinical im-
pact that PLD could have on the association between
chronic inflammation, the general comorbidity, and the
main causes of mortality in HD patients [35].
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